Fig. 10From: A novel dual-prodrug carried by cyclodextrin inclusion complex for the targeting treatment of colon cancerAnti-tumor mechanism assay of BBA/FA-PEG-CM-β-CD (×400). Tumor sections were excised, fixed, dewaxed, and conducted to analyze the endothelial cell marker VEGFR, and the cell proliferation marker ki-67, H&E staining for determining necrosis rate, and TUNEL assay for detection of apoptosis, respectivelyBack to article page